ABDIN Aripiprazole 5mg Tablet 1's
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
Features
- Aripiprazole
Description
Indications/Uses
Dosage/Direction for Use
Adolescents: Aripiprazole (Abdin) tablet is indicated for the treatment of Schizophrenia in adolescents 13 to 17 years of age.
Overdosage
There is no specific antidote for Aripiprazole (Abdin) tablet overdose. For this reason, supportive measures should immediately be taken until the patient recovers. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Early administration of activated charcoal may reduce drug absorption of aripiprazole whereas hemodialysis may not be useful since it is highly protein bound.
Administration
Contraindications
Special Precautions
Use In Pregnancy & Lactation
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms.
Adverse Reactions
Neurological disorders: Neuroleptic Malignant Syndrome (NMS), headache, anxiety, insomnia, lightheadedness, seizures, and drowsiness.
Musculoskeletal disorders: Extrapyramidal effects (common with akathisia), tardive dyskinesia.
Metabolism disorder: Weight gain.
Cardiovascular system disorders: Tachycardia, orthostatic hypotension, bradycardia, ventricular arrhythmias, cardiac arrest, QT prolongation and torsades de pointes.
Drug Interactions
The central effects of other CNS depressants including alcohol may be enhanced by aripiprazole. Aripiprazole may also enhance the effects of antihypertensive drugs. It should be used with caution in patients also receiving drugs that prolong the QT interval or cause electrolyte imbalance. Aripiprazole is metabolized by the cytochrome P450 isoenzymes CYP3A4 and CYP2D6. Ketoconazole, a potent CYP3A4 inhibitor, can increase aripiprazole plasma concentrations by about 60%; licensed product information states that the dose or aripiprazole should be reduced by half when given with ketoconazole. Similarly, the dose of aripiprazole should be halved when given with quinidine, a potent inhibitor of CYP2D6. Conversely, plasma concentration of aripiprazole may decrease by about CYP3A4 inducer, the dose of aripiprazole should be doubled if carbamazepine is added to aripiprazole treatment. Similar effects may occur with other potent inhibitors or inducers of these isoenzymes and a reduced or increased dose of aripiprazole, respectively in such combinations is recommended.
Antiepileptics: Reports of Stevens-Johnson syndrome occur on use of aripiprazole with lamotrigine.
Storage
Action
Pharmacokinetics: Aripiprazole is well absorbed from the gastrointestinal tract after oral doses with peak plasma concentrations reached in about 3 to 5 hours. The absolute bioavailability is reported to be 87% with tablet formulations and it is widely distributed.
It is metabolized mainly in the liver and pathways involved include dehydrogenation and hydroxylation, via the cytochrome P450 isoenzymes CYP3A4 and CYP2D6, and N-dealkylation, via CYP3A4. The major metabolite, dehydro-aripiprazole, is also active and represents about 40% of the plasma levels of aripiprazole. The mean elimination half-lives of aripiprazole and dehydro-aripiprazole are about 75 and 95 hours, respectively; in a minority of poor metabolizers the half-life of aripiprazole maybe extended to about 146 hours.